Caspase inhibitors and uses thereof

Details Caspase inhibitors and uses thereof Caspase inhibitors and uses thereof

2011-06-14

2011-06-14

Andres, Janet L (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S290000

Reexamination Certificate

active

07960415

ABSTRACT:
The present invention provides a compound of formula I:wherein R1, R2, R3, R4, and R5are as defined herein. The present invention also provides pharmaceutical compositions and methods using such compositions for treating a caspase-mediated diseases and processes for preparing the compounds of the invention.

REFERENCES:
patent: 4728647 (1988-03-01), Benavides et al.
patent: 5656627 (1997-08-01), Bemis et al.
patent: 5716929 (1998-02-01), Bemis et al.
patent: 5756466 (1998-05-01), Bemis et al.
patent: 5847135 (1998-12-01), Bemis et al.
patent: 5874424 (1999-02-01), Batchelor et al.
patent: 5973111 (1999-10-01), Bemis et al.
patent: 6025147 (2000-02-01), Bemis et al.
patent: 6103711 (2000-08-01), Bemis et al.
patent: 6184244 (2001-02-01), Karanewsky et al.
patent: 6197750 (2001-03-01), Karanewsky et al.
patent: 6242422 (2001-06-01), Karanewsky et al.
patent: 6420522 (2002-07-01), Bemis et al.
patent: 6525076 (2003-02-01), Zhu et al.
patent: 2003/0162993 (2003-08-01), Mortimore et al.
patent: 2003/0232846 (2003-12-01), Golec et al.
patent: 2004/0019017 (2004-01-01), Mortimore et al.
patent: 2004/0048797 (2004-03-01), Miller et al.
patent: 2004/0072850 (2004-04-01), Knegtel et al.
patent: 2004/0192612 (2004-09-01), Charrier et al.
patent: 2004/0242494 (2004-12-01), Brenchley et al.
patent: 2007/0155718 (2007-07-01), Durrant et al.
patent: 232699 (1986-02-01), None
patent: 058633 (1992-08-01), None
patent: 0528633 (1992-08-01), None
patent: 0509769 (1996-09-01), None
patent: 0761680 (1997-12-01), None
patent: 1203766 (2002-05-01), None
patent: 0826671 (2004-12-01), None
patent: 2292149 (1996-02-01), None
patent: 9316710 (1993-09-01), None
patent: 9321210 (1993-10-01), None
patent: 9526958 (1995-10-01), None
patent: 9535308 (1995-12-01), None
patent: 9603982 (1996-02-01), None
patent: 9640647 (1996-12-01), None
patent: 9816502 (1998-04-01), None
patent: 9816505 (1998-04-01), None
patent: 9818781 (1998-05-01), None
patent: 0023421 (2000-04-01), None
patent: 0061542 (2000-10-01), None
patent: 0067746 (2000-11-01), None
patent: 0068188 (2000-11-01), None
patent: 0142216 (2001-06-01), None
patent: 0194351 (2001-12-01), None
patent: 03024955 (2003-03-01), None
patent: 03042169 (2003-05-01), None
patent: 03068242 (2003-08-01), None
patent: 2004002961 (2004-01-01), None
patent: 2004058718 (2004-07-01), None
patent: 2004106304 (2004-12-01), None
patent: 2006057961 (2006-06-01), None
patent: 2007015931 (2007-02-01), None
patent: 9722619 (2009-06-01), None
Semple, et al., “Pyridone-Based Peptidomimetic Inhibitors of Interleukin-1Beta-Converting Enzyme (ICE),” Bioorganic & Medicinal Chemistry Letters, 7(10):1337-1342 (1997).
Livingston, et al., “In Vitro and In Vivo Studies of ICE Inhibitors,” Journal of Cellular Biochemistry, 64:19-26 (1997).
Husain, et al., “Some New 2-Aryloxymethyl-3-alpha-substituted Carboxymethyl-6, 8-Substituted-4-quinazolones as Possible Anticonvulsants,” Pharmazie, 37:408-410 (1982).
Hussain, et al., “Some Newer Quinazolones as Possible Anticonvulsants,” J. Chem. Soc. Pak., 6(4):211-215 (1984).
Canonne, et al., “Synthesis of Chiral 3-Substituted 2,4 (1H, 3H)-Quinazolinediones,” Heterocycles, 36(6):1305-1314 (1993).
Warner, et al., “Non-peptidic Inhibitors of Human Leukocyte Elastase. 1. The Design and Synthesis of Pyridone-Containing Inhibitors,” J. Med. Chem., 37(19), 3090-3099 (1994).
Gouilleux, et al., “Solid Phase Synthesis of chiral 3-substituted Quinazoline-2, 4-diones,” Tetrahedron Letters, 37 (39):7031-7034 (1996).
Gordeev, et al., “A General and Efficient Solid Phase Synthesis of Quinazoline-2, 4-diones,” Tetrahedron Letters, 38 (10):1729-1732 (1997).
Talanian, et al., “Caspase as Targets for Anti-Inflammatory and Anti-Apoptotic Drug Discovery,” Journal of Medicinal Chemistry, 43(18):3351-3371 (2000).
Lalonde, et al., “Use of a Papain as a Model for the Structure-Based Design of Cathepsin K Inhibitors: Crystal Structures of Two Papain-Inhibitor Complexes Demonstrate Binding to S′-Subsites”, J. Med. Chem., 41:4567-4576 (1998).
Mjalli, et al. “Inhibition of Interleukin-1beta Converting Enzyme By N-Acyl-Aspartic Acid Ketones”, Bioorganic & Medicinal Chemistry Letters, 5 (13);1405-1408 (1995).
Dolle, et al. “Aspartyl alpha-((Diphenylphosphinyl)oxy)methyl Ketones as Novel Inhibitors of Interleukin-1beta Converting Enzyme, Utility of the Diphenylphosphinic Acid Leaving Group for the Inhibition of Cysteine Proteases” J. Med. Chem. 38:220-222 (1995).
Dolle et al, “First Examples of Peptidomimetic Inhibitors of Interleukin-1 Converting Enzyme” J. Med. Chem vol. 39, pp. 2438-2440 (1996).
Patani et al., “Bioisosterism: A Rational Approach in Drug Design”, Chem. Rev., 96(8), 3147-3176, (1996).
Golec et al, “Structure-based design of Non-peptidic Pyridone Aldehydes as Inhibitors of Interleukin-1β-Converting Enzyme” Bioorganic & Medicinal Chem. Letters, 7(17):2181-2186 (1997).
Semple et al. “Peptidomimetic Aminomethylene Ketone Inhibitors of Interleukin-1β-Converting Enzyme (ICE)”, Bioorganic & medicinal Chemistry Letters, 8:959-964, (1998).
Witek et al. “Pan-Caspase Inhibitor VX-166 Reduces Fibrosis in an Animal Model of Nonalcoholic Steatohepatitis”, Hepatology, 50(10):1-10, (2009).
Weber et al. “VX-166: A Novel potent small molecule caspase inhibitor as a potential therapy for sepsis”, Crisitcal Care, 13(5), 1-11, (2009).
Veale, et al., “Nonpeptidic Inhibitors of Human Leukocyte Elastase, 5 Design, Synthesis and X-Ray Crystallography ofa serieds of Orally Active 5-Aminopyrimidin-6-one Containing Trufluorometheyl Ketones”, J. Med. Chem., 38(1), 98-108, (1995).
Damewood, James R., et al., “Nonpeptidic Inhibitors of Human Leukocycte Elastase. 2. Design, Synthesis, and in Vitro Activity of a Series of 3-Amino-6-arylopyridin-2-one Trifluoromethyl Ketones”, J. Med. Chem., 37, 303-3312, (1994).
Erlanson et al., “In situ assembly of enzyme inhibitors using extended tethering” Nature Biotechnology, 21 (3):308-314, (2003).
Dragovich, Peter S., et al., “Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable , 2-pyridone-containing peptidomimetics”, J. Med. Chem., 45,1607-1623, (2002).
Ellis et al., “Mechanisms and functions of cell death”, Annual review cell biology, 7, 663, (1991).
Yaoita, Hiroyuki et al., “Attenuation of ischemia/reperfusion injury in rats by a caspase inhibitor”, Circulation, 97, 276-281 (1998).
Cheng,Yu et al., “Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury”, Journal of Clinical Investigation, 101, 1992-1999 (1998).
Yakovlev, Alexander G. et al., “Activation of CPP32-like caspases contributes to neuronal apoptosis and neurological dysfunction after traumatic brain injury”, The Journal of Neuroscience, 17, 7415-7424, (1997).
Rodriguez, Ivan et al., “Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against fas-mediated fulminant liver destruction and death”, Journal of Experimental Medicine,184, 2067-2072, (1996).
Grobmyer et al., “Peptidomimetic fluoromethylketone rescues mice from lethal endotoxic shock”, 5, 585, (1999).
Plattner, JJ et al., “Obstacles to Drug Development from Peptide Leads”, Drug Discovery Technologies, 93-126, (1990).
Golstein, Pierre, “Cell Death in Us and Others”, Science, 281, 1283-1284, (1998).
Rano, Thomas et al., “A combinatorial approach for determining protease specificites: application to interleukin-1β converting enzyme (ICE)”, Chemistry & Biology, 2, 4, 149-155, (1997).
Mjalli, Adnan M

Affiliated with

Also associated with

Rating

Caspase inhibitors and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Caspase inhibitors and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Caspase inhibitors and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2698624